Clinical Trials Logo

Esophagitis clinical trials

View clinical trials related to Esophagitis.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04835168 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Start date: January 30, 2022
Phase: Phase 1
Study type: Interventional

The proposed Phase 1b study design was a randomized, placebo-controlled, double-blind, study to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.

NCT ID: NCT03834298 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Non-endoscopic Tracking of Disease Activity in Eosinophilic Esophagitis

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

To prospectively determine the natural history of inflammation resolution following initiation of diet treatment and to optimize the diet treatment of patients with EoE through the use of a non-endoscopic tracking device, the esophageal string test (EST).

NCT ID: NCT03803527 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Metabolomic Profiling of Eosinophilic Esophagitis

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

A prospective longitudinal, observational study of adolescent and adults that will identify novel metabolites associated with dysphagia in Eosinophilic Esophagitis (EoE).

NCT ID: NCT03354221 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Short Duration 6Fed Sponge For EoE Patients

Start date: August 2017
Phase: N/A
Study type: Interventional

This research is being done to see if the investigators can use the cytosponge or esophacap (depending on availability) to determine if shorter duration SFED (two weeks versus six weeks) would have equal results.

NCT ID: NCT02986685 Withdrawn - Clinical trials for Refractory Reflux Esophagitis

Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole

rRE
Start date: November 2016
Phase: Phase 4
Study type: Interventional

The research aims to investigate whether trimebutine maleate combined with rabeprazole can improve the clinical efficacy in patients With refractory Los Angeles grade A or B reflux esophagitis . A total of 500 patients with Grade A or B reflux esophagitis refractory to rabeprazole will be randomly divided into two groups.One will continue to receive rabeprazole treatment,and the other group will receive extra oral trimebutine maleate 200 mg three times daily for 4 weeks. The end of the study for every patient is the improvement of main symptoms. The primary and secondary analyses are the main symptoms score, endoscopy results, Gastroesophageal reflux disease questionnaire(GerdQ) score,Hospital Anxiety and Depression Scale(HADS) score, Athens insomnia scale and World Health Organization Quality of Life-Bref(WHOQOL-BREF)scale scores at the baseline and final assessments.

NCT ID: NCT02881372 Withdrawn - Clinical trials for Eosinophilic Esophagitis

EoE Food Desensitization

Start date: August 8, 2018
Phase: N/A
Study type: Interventional

This is a single-center, prospective, pilot clinical trial in which children ages 3-17 years with eosinophilic esophagitis (EoE) who have a known food that triggers EoE flares receive oral desensitization with that specific food antigen, followed by reintroduction of that food into the diet. The purpose of this study is to investigate the safety and feasibility of oral desensitization in children with EoE so that, if determined to be safe, can be repeated on a larger scale to determine efficacy.

NCT ID: NCT01824199 Withdrawn - Esophagitis Clinical Trials

CYP2C19 Genotype Predictor of Gastric Acid Suppression

Start date: March 2013
Phase: Early Phase 1
Study type: Interventional

If CYP2C19 genotype can predict the efficacy of healing erosive esophagitis and gastric acid secretion in patients taking once a day omeprazole.

NCT ID: NCT01779154 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Eosinophilic Gastrointestinal Disorders Patient Registry

Start date: January 2013
Phase: N/A
Study type: Observational [Patient Registry]

The Eosinophilic Gastrointestinal Disorders (EGIDS) Registry is a longitudinal study that does not involve medical interventions, but serves as a record of demographics, characteristics of disease and treatment, utilization patterns, quality improvement measures and clinical outcomes. The database is proposed so that epidemiologic research can be performed and current and accurate data can be obtained regarding practice patterns, age and gender distributions, efficacy of treatment, clinical outcomes and changes in quality of life.

NCT ID: NCT01702701 Withdrawn - Dysphagia Clinical Trials

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

Start date: January 2012
Phase: Phase 3
Study type: Interventional

This study will compare response to treatment of Eosinophilic Esophagitis with montelukast vs standard therapy fluticasone. Investigators hypothesize that montelukast is equally effective in treating symptoms and histology of EoE when compared to fluticasone. The study will be conducted at multiple sites with Medical College of Wisconsin as the coordinating site. After identification and recruitment all patients will be randomized (provider blinded) to one of two medications: montelukast 10mg po qday vs fluticasone 440mcg po bid. Patients will also complete a pretreatment, 6 week therapy and 12 week therapy questionaire. They will then undergo a repeat endoscopy to evaluate endoscopic and histologic response.

NCT ID: NCT01685034 Withdrawn - Clinical trials for Eosinophilic Esophagitis

Allergy Immunotherapy in the Management of Eosinophilic Esophagitis

AIMEE
Start date: n/a
Phase: N/A
Study type: Interventional

Eosinophilic esophagitis (EoE) is a disease that has increased in incidence over the past decade that affects males predominantly, and in adults, is characterized by heartburn, dysphagia, strictures and food impactions. These symptoms may require emergent endoscopic removal of foods and esophageal dilations due to remodeling causing significant impairment in quality of life. Treatment options are limited and often not well tolerated or effective. There is poor understanding of the natural history and long term prognosis. It has been associated with allergic sensitization; a high percentage of affected individuals having associated atopy and current literature demonstrates a seasonal distribution of incidence and severity of symptoms. Allergy immunotherapy (AIT) is a well established and effective treatment for allergic rhinitis and asthma which can induce tolerance to environmental allergens. Given the efficacy of AIT and the association of aeroallergen sensitization and even seasonal variation of EoE symptoms, we hypothesized that AIT may be a treatment option for patients with EoE.